Suryanarayanan Vandhana

Therapeutic and Toxicologic Evaluation of Anti‐Lipogenic Agents in Cancer Cells Compared with Non‐Neoplastic Cells

P. R. Deepa, Suryanarayanan Vandhana, U Jayanthi et al. · Basic & Clinical Pharmacology & Toxicology · 2011 · 61 citations · Full text

Medicine, Oncology, Pharmacology +15

Bio-conjugation of antioxidant peptide on surface-modified gold nanoparticles: a novel approach to enhance the radical scavenging property in cancer cell

Sushma Kalmodia, Suryanarayanan Vandhana, B. R. Tejaswini Rama et al. · Cancer Nanotechnology · 2016 · 46 citations · Full text

Pharmacy, Oncology, Pharmacology +17

Biochemical changes accompanying apoptotic cell death in retinoblastoma cancer cells treated with lipogenic enzyme inhibitors

Suryanarayanan Vandhana, Karunakaran Coral, U Jayanthi et al. · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · 2013 · 36 citations

Life Sciences, Biochemistry, Cell Biology +17

Chemical inhibition of fatty acid synthase: molecular docking analysis and biochemical validation in ocular cancer cells

P. R. Deepa, Suryanarayanan Vandhana, S. Muthukumaran et al. · Journal of ocular biology, diseases, and informatics · 2010 · 35 citations · Full text

Life Sciences, Medicinal Chemistry, Pharmacology +17

Evaluation of suitable solvents for testing the anti-proliferative activity of triclosan - a hydrophobic drug in cell culture.

Suryanarayanan Vandhana, P. R. Deepa, G. Aparna et al. · PubMed · 2010 · 30 citations

Pharmacy, Medicinal Chemistry, Pharmacology +14